The China birth cohort study (CBCS)

Wentao Yue, Enjie Zhang, Ruixia Liu, Yue Zhang, Chengrong Wang, Shen Gao, Shaofei Su, Xiao Gao, Qingqing Wu, Xiaokui Yang, Aris T. Papageorghiou, Chenghong YinEuropean 2022 · DOI

Abstract

The China Birth Cohort Study (CBCS) is a landmark prospective longitudinal study, representing the first national-scale effort to investigate the complex interplay of environmental and genetic factors contributing to birth defects in China. With a target recruitment of 500,000 pregnant women across diverse geographical regions, the study aims to identify modifiable risk factors and develop targeted prevention strategies. To date, the first two phases have enrolled 120,377 participants, revealing an initial birth defect incidence of 2.5%, with congenital heart disease as the most prevalent condition. By integrating clinical data with a robust biobank, the CBCS provides a critical resource for understanding maternal-fetal health in a rapidly developing nation.

Introduction: Addressing the Burden of Birth Defects

Birth defects remain a significant global health challenge, serving as a leading cause of infant mortality and long-term disability. In China, the prevalence is estimated at 5.6%, translating to approximately 900,000 affected infants annually. While Western nations have long utilized birth cohorts to study these issues, there is a profound lack of large-scale data specific to the Chinese "exposotype"—the unique combination of environmental, lifestyle, and medical exposures encountered during China's rapid industrialization and urbanization.

The CBCS was established to bridge this gap. By focusing on a representative population, the study seeks to move beyond simple correlations to uncover the causal pathways of congenital malformations, particularly those related to environmental pollutants and changing socioeconomic conditions.

Methods and Study Design

The CBCS is structured as a prospective longitudinal mega-cohort study, executed in three distinct phases: pilot, evaluation, and expansion. Recruitment targets pregnant women of Chinese nationality between 6 and 13<sup>+6</sup> weeks of gestation who plan to deliver at one of the 38 participating research sites across 17 provinces.

Figure 2: Flowchart of the CBCS study design, illustrating the recruitment and follow-up stages through delivery.

As shown in Figure 2, the study follows a rigorous protocol of in-person interviews and clinical assessments at four critical milestones:

  1. Enrollment: Early pregnancy (6–13<sup>+6</sup> weeks).
  2. 1st Follow-up: Mid-pregnancy (20–23<sup>+6</sup> weeks).
  3. 2nd Follow-up: Late pregnancy (28–33<sup>+6</sup> weeks).
  4. 3rd Follow-up: Delivery.

Data management is handled via a secure, cloud-based Electronic Data Capture (EDC) system integrated with a biobank management module. This setup ensures real-time data transfer and automated validation. Furthermore, the study employs a nested case-control design; for every birth defect identified, two matched controls are selected based on maternal and gestational age to facilitate comparative analysis.

Initial Datasets and Geographic Distribution

The first two phases of the study (November 2017 to February 2020) successfully enrolled 120,377 eligible pregnant women. Of these, 40,837 have been followed through to the completion of their pregnancy.

Figure 1: Geographic distribution of recruitment across China, highlighting the number of participants by province.

The recruitment effort spans a wide geographical area to ensure national representation. As illustrated in Figure 1, major hubs include Beijing (35,890 participants) and Shandong (17,866 participants), with significant contributions from provinces like Henan, Guangdong, and Yunnan. This diversity is essential for capturing the varied environmental exposures across China.

In addition to clinical data, the study has established a comprehensive biobank. Samples collected include peripheral blood, amniocytes, cord blood, placenta, and umbilical cord tissue, providing a rich substrate for future "omics" research.

Key Insights and Preliminary Results

Preliminary analysis of the cohort has yielded several important findings:

  • Incidence of Defects: The current incidence rate of birth defects within the cohort is 2.5%. Congenital heart disease is the most frequent malformation, followed by urinary/genital system defects and chromosomal abnormalities.
  • Paternal Factors: A unique strength of the CBCS is the inclusion of paternal data. While maternal smoking and alcohol use are negligible (<1%), paternal rates are significantly higher (33.8% for smoking and 31.9% for alcohol), offering a vital window into epigenetic influences on fetal development.
  • Demographic Profile: The average maternal age is 30.08 years. The cohort is relatively well-educated, with approximately 65% of participants holding at least an undergraduate degree.
  • Standardization: To maintain data quality across 38 sites, the study utilizes standardized ultrasound protocols and the INTERGROWTH-21st international standards for newborn measurements.

Limitations and Future Outlook

While the CBCS is unprecedented in scale, it faces certain limitations. The reliance on "3A" hospitals (top-tier medical centers) may introduce selection bias toward urban and higher-risk populations. Additionally, the current reliance on self-reported questionnaires for lifestyle data introduces potential recall bias. Because the study currently concludes at delivery, late-manifesting defects may be under-reported.

Future phases of the CBCS aim to expand recruitment to the full 500,000 target and transition into a long-term "life cycle" follow-up. This will involve tracking the health of the children over several years and integrating advanced genomic sequencing to further unravel the complex etiology of birth defects in the Chinese population.

Summary updated

Abstract

The China birth cohort study (CBCS) is a prospective longitudinal, mega-cohort study and the first national-based birth cohort study, aiming to establish a birth cohort covering representative geographical areas of the whole of China to investigate risk factors for birth defects and develop strategies for their reduction. Pregnant women who are of Chinese nationality, are 6-13<sup>+6</sup> weeks of gestation, plan to attend the routine antenatal examination and deliver in the study site, and give their informed, written consent are eligible to participate in this study. All participants are followed-up through an in-person interview at 20-23<sup>+6</sup> weeks and again at 28-33<sup>+6</sup> weeks of gestation, and at delivery, respectively. CBCS has been divided into three phases from 20th November 2017 to 31st December 2021, and the first two phases have now been completed on 29th February 2020, enrolling 120 377 eligible pregnant women during this period. During the same period a total of 40 837 participants had been followed up to the end of pregnancy. Study recruitment will continue until December 2021 to achieve the target of 500 000 participants. Meanwhile, biological samples including peripheral blood, amniocytes, cord blood, placenta, or umbilical cord tissue have been collected from participants according to various conditions. The incidence of birth defects in this group is 2.5% and congenital heart disease is the most common type of birth defect seen so far. A website is in the advanced stages of planning, to allow seamless data transfer and facilitate collaboration with groups around the world.
BibTeX
@inproceedings{yue2022china,
  author = {Wentao Yue and Enjie Zhang and Ruixia Liu and Yue Zhang and Chengrong Wang and Shen Gao and Shaofei Su and Xiao Gao and Qingqing Wu and Xiaokui Yang and Aris T. Papageorghiou and Chenghong Yin},
  title = {{The China birth cohort study (CBCS)}},
  booktitle = {European},
  year = {2022},
  doi = {10.1007/s10654-021-00831-8},
}
Figure